<div id="readability-page-1"><p>Montecito Bank &amp; Trust acquired a new stake in  Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,959 shares of the medical research company's stock, valued at approximately $1,435,000.</p><ul><li>Institutions Love These 3 Companies, Should You As Well?</li></ul><p>A number of other institutional investors have also modified their holdings of TMO. New Covenant Trust Company N.A. purchased a new stake in shares of  Thermo Fisher Scientific in the third quarter valued at approximately $228,000.  McLean Asset Management Corp lifted its holdings in shares of  Thermo Fisher Scientific by 4.7% in the 3rd quarter. McLean Asset Management Corp now owns 627 shares of the medical research company's stock worth $304,000 after buying an additional 28 shares during the period.  Channel Wealth LLC bought a new position in shares of  Thermo Fisher Scientific during the 3rd quarter worth $210,000.  ST Germain D J Co. Inc. raised its holdings in shares of  Thermo Fisher Scientific by 7.7% in the third quarter. ST Germain D J Co. Inc. now owns 3,947 shares of the medical research company's stock valued at $1,914,000 after acquiring an additional 281 shares in the last quarter.  Finally, Grant Private Wealth Management Inc purchased a new stake in  Thermo Fisher Scientific in the third quarter worth about $457,000. 89.23% of the stock is owned by hedge funds and other institutional investors. </p><h2>Thermo Fisher Scientific Stock Performance</h2><p>Shares of TMO opened at $562.58 on Thursday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The stock has a fifty day moving average price of $567.63 and a 200-day moving average price of $495.07. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The firm has a market cap of $211.37 billion, a PE ratio of 32.50, a P/E/G ratio of 4.22 and a beta of 0.90. </p><ul><li>These 3 Stocks Are Using Buybacks to Signal Market Confidence</li></ul><p>Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm's quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the company posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS.  Equities research analysts predict that  Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year. </p><p>Thermo Fisher Scientific declared that its Board of Directors has initiated a stock repurchase program on Thursday, November 6th that permits the company to repurchase $5.00 billion in    shares. This repurchase authorization permits the medical research company to repurchase up to 2.4% of its stock  through open market purchases. Stock  repurchase programs are typically an indication that the company's leadership believes its stock is undervalued. </p><h2>Thermo Fisher Scientific Dividend Announcement</h2><ul><li>Cash Flow Focus: Thermo Fisher, Energy Transfer, and NetEase</li></ul><p>The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.94%. </p><h2>Insider Activity at Thermo Fisher Scientific</h2><p>In related news, COO Michel Lagarde sold 22,046 shares of the company's stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $563.56, for a total value of $12,424,243.76. Following the transaction, the chief operating officer directly owned 84,117 shares of the company's stock, valued at $47,404,976.52. This represents a 20.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, VP Lisa P. Britt sold 1,058 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total value of $622,379.08. Following the sale, the vice president directly owned 13,087 shares of the company's stock, valued at approximately $7,698,558.62. This represents a 7.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 149,271 shares of company stock worth $86,507,282 in the last 90 days. 0.33% of the stock is owned by insiders. </p><h2>Wall Street Analyst Weigh In</h2><p>TMO has been the subject of several recent research reports. Weiss Ratings  restated a &#34;hold (c)&#34; rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, December 2nd. Citigroup raised Thermo Fisher Scientific from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and increased their target price for the company from $580.00 to $660.00 in a research report on Thursday, December 11th. Evercore ISI boosted their price target on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, October 7th. Finally, Hsbc Global Res upgraded Thermo Fisher Scientific from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Monday, December 1st. One research analyst  has rated the stock with a Strong Buy rating, twenty have issued  a Buy rating and three have assigned  a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific  has an average rating of &#34;Moderate Buy&#34; and an average target price of $616.60.</p><p><b>Read Our Latest Research Report on TMO</b></p><h2>Thermo Fisher Scientific Profile</h2> (Free Report)<p>Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Thermo Fisher Scientific</li><li>Buy P&amp;G Now, Before It Sets A New All-Time High</li><li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li><li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li><li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li><li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li><li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Thermo Fisher Scientific Right Now?</h2><p>Before you consider Thermo Fisher Scientific, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.</p><p>While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Montecito Bank & Trust acquired 2,959 shares of Thermo Fisher Scientific Inc., valued at $1,435,000, in the third quarter. Other institutional investors also modified their holdings. Thermo Fisher's stock opened at $562.58, with a market cap of $211.37 billion. The company reported $5.79 EPS for the quarter, beating estimates. A $5 billion stock repurchase program was initiated, and a quarterly dividend of $0.43 was announced. Insider sales included COO Michel Lagarde selling 22,046 shares.</p>

2,959 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Montecito Bank & Trust